MMMaria Martinez-Lage

Maria Martinez-Lage

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Martinez-Lage has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A 35-Year-Old Woman With Multiple Sclerosis and a New Atypical Thalamic Lesion

    by Nara Miriam Michaelson, Isabel C. Arrillaga-Romany, Justin T. Jordan, Maria Martinez-Lage, Claire Riley, Scott S. Zamvil, Myla D. Goldman, Eric C. Klawiter

    In multiple sclerosis (MS), new or enlarging brain lesions often suggest disease activity, but infections or tumors may mimic relapse. We report a 35-year-old woman with MS whose enlarging thalamic...

  • Emergence of inactivating NOTCH1 mutations in an IDH-mutant astrocytoma with clinical resistance to vorasidenib treatment

    by Tomoyuki Nakano, Nicholas A Jessop, Charlotte I Wang, Maria Martinez-Lage, Itay Tirosh, Mario L Suva, Hiroaki Wakimoto, Daniel P Cahill, Christine Lu-Emerson, Julie J Miller


  • Characterization of Clinical Course, Diagnosis, Treatment, and Outcomes of Intravascular Lymphoma With Neurologic Involvement

    by Lucas Horta, Bruna Leles Vieira de Souza, Maria Martinez-Lage, Deborah Forst, Denis Balaban

  • Open Access

    Oxidized protein states define metastatic fitness in lung cancer

    by Maolin Ge, Magdy Gohar, Consuelo Torrini, Yukako Suzuki, Shan Jiang, Yuchen Huang, Benjamin Weinstein, Janice Wong, Naema Nayyar, Md Yousuf Ali, et al.

    Reactive oxygen species (ROS) are a pervasive feature of human cancers, yet the protein targets through which ROS-regulated cell states shape tumor biology remains poorly understood. Here, using cysteine chemical proteomics, we define signatures of protein states under distinct cellular ROS environments that capture protein oxidation and conformational changes. Quantifying these signatures in primary lung tumors and brain metastases revealed a surprising enrichment of oxidative states in metastasis. To determine how these states support fitness, we performed genome-wide CRISPR screens and identified the mitochondrial Complex I subunit NDUFA10 as a key oxidation-dependent vulnerability. Oxidation of NDUFA10•Cys253 supports Complex I function through a previously unrecognized nucleotide kinase activity that maintains mitochondrial DNA levels. Enforcing a reduced conformation in NDUFA10 disrupts brain metastatic colonization in vivo . These findings establish ROS regulated protein states as a functional layer of tumor fitness, providing a framework for identifying redox-dependent mechanisms that support cancer progression.


  • Clinical Manifestations of Primary CNS T-Cell Lymphoma

    by Katharina Johanna Müller, Philipp Karschnia, Leon D. Kaulen, Jonas Reis, Georgios Gakis, Benjamin Englert, Felix Hinz, Benjamin-Leon Traub, Felix Ehret, Elizabeth C. Conner, et al.

    Primary CNS T-cell lymphoma (PCNSTL) is an extremely rare and aggressive form of non-Hodgkin lymphoma. Diagnosis is often challenging because of the nonspecific clinical presentation, which can lead to delays in treatment. This study aims to analyze the clinical, histopathologic, and neuroimaging characteristics of PCNSTL. In this retrospective, multicentric cohort study, histologically confirmed PCNSTL cases without evidence of systemic disease were selected from pathology databases at 3 academic neuro-oncology centers (University Hospital of Munich, University Hospital of Heidelberg, Massachusetts General Hospital in Boston) during the period from 2008 to 2024. Retrospective data, including demographics, histopathology, immunophenotyping, multimodal MRI, and PET imaging, treatment lines, and outcome data were extracted from medical records and analyzed. We evaluated 16 patients (11 male) with a median age of 50 years (19-76 years) and a median Karnofsky performance status of 80% (20%-100%). T-cell clonality was confirmed in 9/15 (60%) tested patients with typical T-cell receptor gene rearrangement patterns. MRI scans at primary diagnosis showed predominantly supratentorial parenchymal lesions with prominent contrast enhancement in 14/16 (87.5%) and in more than one-third multifocal lesions (7/16, 43.75%). High intratumoral susceptibility signal was frequently observed (7/16, 43.75%). [18F]fluorodeoxyglucose-PET and [18F]fluoroethyltyrosine-PET imaging revealed only low to moderate tracer uptake in 7/8 examined patients (87.5%). Median progression-free survival was 4 months, and median overall survival was 97.5 months. Although treatment protocols varied, the use of methotrexate (MTX)-based chemotherapy combined with autologous stem-cell transplant (ASCT) was associated with most favorable outcome (95% CI 2-87, p < 0.0275). In 1 case of ALK1-positive PCNSTL, persistent complete remission was achieved after treatment with the ALK-inhibitor lorlatinib. Although PCNSTL is exceptionally rare, we identified distinct neuroimaging patterns showing highly aggressive features on MRI but hypometabolic PET imaging, which may assist in identifying future PCNSTL cases. Despite the limited cohort size, our findings suggest that MTX-based chemotherapy with ASCT may translate into favorable outcome. We report on an ALK1-positive PCNSTL case with sustained complete remission after targeted therapy with lorlatinib.


  • Top Cited Papers
    Open Access

    Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial

    by Priscilla K. Brastianos, Katharine Dooley, Susan Geyer, Elizabeth R. Gerstner, Timothy J. Kaufmann, A. John Iafrate, Maria Martinez-Lage, Mohammed Milhem, Mary Roberta Welch, Thomas J. Kaley, et al.

    Systemic treatments are limited for patients with meningiomas that have progressed after surgery or radiation. Loss of NF2 and CDKN2A/ CDKN2B is common in higher-grade meningiomas and promotes progression in preclinical models. We evaluated the efficacy of abemaciclib, a cyclin-dependent kinase 4/6 inhibitor, as one arm of the Alliance umbrella trial A071401, a genomically driven phase 2 study in recurrent and progressive meningiomas. Eligible patients with grade 2 or 3 tumors and NF2 mutations or CDK pathway alterations were treated with abemaciclib. Two co-primary endpoints were used: progression-free survival at 6 months (PFS6) and response rate as defined by local review; the trial would be declared positive if either endpoint was met. The success threshold for PFS6 was 8 or more of 24 patients; for the response rate, it was 3 or more of 24 patients. Ninety-six patients were screened and 36 patients received treatment. The mean number of treatment cycles was nine and the median follow-up was 21 months. The first 24 patients who met the eligibility criteria and began treatment could be evaluated for the primary endpoint. The observed PFS6 rate was 58% (14 of 24 patients, 95% confidence interval = 37–78%), thus meeting the PFS6 criteria for promising activity. The best response was stable disease in 16 of 24 patients. Of the 36 patients who started treatment, nine had a grade 3 and two had grade 4 adverse events at least possibly related to treatment. Grade 4 toxicities included alanine aminotransferase elevation (1), aspartate aminotransferase elevation (1) and vomiting (1). The trial met its primary endpoint. Abemaciclib was well tolerated and resulted in improved PFS6. Abemaciclib warrants further investigation for patients with progressive grade 2 or 3 meningiomas harboring NF2 or CDK pathway alterations. ClinicalTrials.gov registration no. NCT02523014 .


  • Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy

    by Leon D. Kaulen, Maria Martinez-Lage, Jeremy S. Abramson, Philipp Karschnia, Sofia Doubrovinskaia, Ganesh M. Shankar, Bryan D. Choi, Christopher M. Ramundo, Felix Ehret, Jeffrey A. Barnes, et al.

    Tumor inflammation-associated neurotoxicity (TIAN) was recently proposed as a unique complication of immunotherapy in patients with brain tumor. Here, we report a first comprehensive characterization of TIAN in patients with central nervous system (CNS) lymphoma (CNSL) treated with CD19-directed chimeric antigen receptor (CD19-CAR) T cells. TIAN occurred in 10 of 56 (17.9%) patients with CNSL, with clinical onset at a median 3.5 days (range, 1-9) after CD19-CAR T-cell infusion. It was less frequently associated with cytokine release syndrome (60% vs 100%; P = .009) than immune effector cell–associated neurotoxicity syndrome (ICANS). Although symptoms were usually transient and fully reversible, TIAN was associated with a fatal outcome in 1 patient. Larger CNS tumor volume at baseline allowed the identification of patients at risk for TIAN (area under the curve, 0.847; P = .002). Maximizing Youden J statistics, a discriminatory tumor volume threshold of >3.4 cm3 was determined, which carried 87.5% sensitivity and 80.5% specificity. TIAN correlated with higher overall response rates to CD19-CAR T cells (90% vs 52%; P = .036) and improved progression-free survival (hazard ratio, 0.22; 95% confidence interval, 0.07-0.61; P = .006) on multivariate Cox proportional hazard regression. Postmortem histopathological evaluation of a TIAN lesion revealed a dense macrophage population with central necrosis and peripheral reactive gliosis, accompanied by loss of white matter and intracytoplasmic myelin in foamy macrophages. Collectively, our work supports TIAN as a localized on-tumor, on-target neurotoxicity syndrome, closely related to preexisting CNSL lesions and distinct from ICANS. CNS tumor volume at baseline may allow to identify patients at risk and may guide management.


  • Implementing the Promotion in Place Model of Competency-Based Time-Variable Graduate Medical Education in Pathology

    by Maria Martinez-Lage, Mary Ellen J. Goldhamer, Martin V. Pusic, John A. Branda, Debra F. Weinstein, W. Stephen Black-Schaffer, John Patrick T. Co

    Background Promotion in Place (PIP) is a competency-based time-variable graduate medical education innovation model developed at Mass General Brigham and not previously tested for feasibility, acceptability, or outcomes. Objective To assess early PIP outcomes in the Massachusetts General Hospital (MGH) pathology residency program. Methods Approved by the American Board of Pathology, PIP was launched in 2021. The Clinical Competency Committee developed and implemented explicit graduation criteria. Trainees meeting criteria who chose early graduation became credentialed, board-eligible junior attendings at MGH in a period of “sheltered independence” and were assessed using the Focused Professional Practice Evaluation. PIP sheltered independence (PIP-SI) participation rates, time, and activities were followed. We also assessed board pass rates, Milestones, and patient safety reports for all residents. We measured additional participant time and resources. Results Over 4 years, 24 of 30 (80%) residents qualified for PIP-SI, 17 of 24 (71%) accepted, and 7 of 24 (29%) declined. Eleven of 17 (65%) had a period of sheltered independence as junior attendings (median 9 weeks [range 5-24 weeks]) in various anatomic and clinical pathology roles. Of 6 eligible residents not participating, 4 took a leave of absence, and 2 experienced licensing or visa delays. All residents passed their board examinations on the initial attempt and none had concerns identified through patient safety reports. Time and resource requirements were acceptable to stakeholders. Conclusions Most residents met criteria for PIP-SI and accepted, demonstrating high acceptability. PIP-SI was feasible with implementation into standard workflows over 4 years. PIP-SI attendings had no adverse outcomes identified.


  • Clinical Reasoning: Assessing New Neurologic Deficits in Patients With Hematologic Malignancy on Bruton Tyrosine Kinase Inhibitor Therapy

    by Thomas A. Nelson, Naina K. Murthy, Maria Martinez-Lage, Jeremy Abramson, Andrew R. Branagan, Yongli Ji, Yi-Bin A. Chen, Alyssa R. Letourneau, Brian V. Nahed, Isabel C. Arrillaga-Romany, et al.


  • Perineuroma Caused Isolated Footdrop

    by Stephen Chrzanowski, Christopher Mount, Maria Martinez-Lage, Bragi Sveinsson, Justin Brown, Reza Sadjadi